Palisade Bio Secures $3M Investment to Accelerate PALI-2108 Phase 2 UC Study Enrollment
Summary
Palisade Bio raised $3.0 million in a private placement at a premium to current market price, concurrently entering a strategic partnership to accelerate Phase 2 study enrollment for its PALI-2108 ulcerative colitis program.
Key Events
-
Strategic Partnership for Phase 2 Study
Palisade Bio entered into a master services agreement with Iterative Health on March 30, 2026, to assist with patient enrollment for the upcoming Phase 2 clinical study of PALI-2108 for Ulcerative Colitis.
-
$3 Million Private Placement Completed
On March 27, 2026, the company issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health for a total purchase price of $3.0 million.
-
Shares Priced at a Premium
The shares were sold at $1.952 per share, which represents the average closing price of the common stock for the five trading days prior to the closing date, and is a premium to the current stock price of $1.84.
Analysis
Palisade Bio has strategically raised $3.0 million through a private placement, issuing shares at a premium to the current market price. This capital is directly linked to a new master services agreement with Iterative Health, aimed at expediting patient enrollment for the crucial Phase 2 study of PALI-2108 in Ulcerative Colitis. This move signals continued progress in their clinical pipeline, building on the recent positive Phase 1b data for PALI-2108 in Crohn's disease. The financing, while modest compared to the company's overall market cap, is a targeted investment to advance a key asset and demonstrates confidence from a strategic partner.
At the time of this filing, PALI was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $311.9M. The 52-week trading range was $0.53 to $2.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.